News
Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...
Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...
About a dozen activists from the Extinction Rebellion climate group briefly occupied the entrance lobby of French bank BNP ...
16h
Zacks.com on MSN3 Stocks Targeting Weight Loss Market With Cannabinoid-Based TherapiesNVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid ...
(Reuters) -After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective weight-loss drugs ...
Zacks highlights LLY, GE, and AMGN as top picks, citing strong demand, product pipelines, and defense tailwinds despite some ...
19h
The Holy Mess on MSNGLP-1 Weight Loss Drugs: Miracle, Mess, or Something in Between?Unless you are from another planet, you’ve heard all about the new weight loss medications taking the world by storm. These ...
Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.
A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to ...
As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.
By Sriparna Roy (Reuters) -After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective ...
Plus, peek inside Raleigh’s newest data center, a Duke researcher reflects on her canceled federal grant amid buyouts, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results